MA28428B1 - FORMES SALINES DE 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO) PHENYL]-BENZAMIDE - Google Patents

FORMES SALINES DE 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO) PHENYL]-BENZAMIDE

Info

Publication number
MA28428B1
MA28428B1 MA29225A MA29225A MA28428B1 MA 28428 B1 MA28428 B1 MA 28428B1 MA 29225 A MA29225 A MA 29225A MA 29225 A MA29225 A MA 29225A MA 28428 B1 MA28428 B1 MA 28428B1
Authority
MA
Morocco
Prior art keywords
salt
methyl
benzamide
phenyl
tartrate
Prior art date
Application number
MA29225A
Other languages
English (en)
Inventor
Hans Michael Burger
Paul William Manley
Michael Mutz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28428(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA28428B1 publication Critical patent/MA28428B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne des sels d'addition d'acides de 4-[(4-méthyl-1-pipérazinyl)méthyl]-N-[4-méthyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phényl]-benzamide, qui sont choisis dans le groupe constitué par un sel de tartrate, tel qu'un sel de (D)(-)-tartrate ou un sel de (L)(+)-tartrate, un sel de chlorhydrate, un sel de citrate, un sel de malate, un sel de fumarate, un sel de succinate, un sel de benzoate, un sel de benzènesulfonate, un sel de pamoate, un sel de formiate, un sel de malonate, un sel de 1,5-naphtalènedisulfonate, un sel de salicylate, un sel de cyclohexanesulfamate, un sel de lactate, un sel de mandélate, un sel de glutarate, un sel d'adipate, un sel de squarate, un sel de vanillate, un sel d'oxaloacétate, un sel d'ascorbate et un sel de sulfate.
MA29225A 2004-02-04 2006-08-01 FORMES SALINES DE 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO) PHENYL]-BENZAMIDE MA28428B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54181704P 2004-02-04 2004-02-04

Publications (1)

Publication Number Publication Date
MA28428B1 true MA28428B1 (fr) 2007-02-01

Family

ID=34837520

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29225A MA28428B1 (fr) 2004-02-04 2006-08-01 FORMES SALINES DE 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO) PHENYL]-BENZAMIDE

Country Status (22)

Country Link
US (3) US20080249104A1 (fr)
EP (1) EP1713792B1 (fr)
JP (1) JP4937760B2 (fr)
KR (2) KR20060135735A (fr)
CN (1) CN100558723C (fr)
AR (1) AR047530A1 (fr)
AU (1) AU2005211514B2 (fr)
BR (1) BRPI0507464A (fr)
CA (1) CA2553887C (fr)
EC (1) ECSP066752A (fr)
IL (1) IL177005A (fr)
MA (1) MA28428B1 (fr)
MY (1) MY144177A (fr)
NO (1) NO20063942L (fr)
NZ (1) NZ548714A (fr)
PE (1) PE20051096A1 (fr)
PH (1) PH12013500157A1 (fr)
RU (1) RU2375355C2 (fr)
TN (1) TNSN06243A1 (fr)
TW (1) TWI347186B (fr)
WO (1) WO2005075454A2 (fr)
ZA (1) ZA200605972B (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
JP5844508B2 (ja) 2005-11-25 2016-01-20 ノバルティス アーゲー メシル酸イマチニブのｆ結晶形
KR100799821B1 (ko) * 2007-02-05 2008-01-31 동화약품공업주식회사 신규한 이마티닙 캠실레이트 및 그의 제조방법
US7550591B2 (en) 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
WO2008136010A1 (fr) * 2007-05-07 2008-11-13 Natco Pharma Limited Procédé de préparation de l'imatinib base hautement pure
WO2009036753A2 (fr) * 2007-09-20 2009-03-26 Schebo Biotech Ag Nouveaux produits pharmaceutiques, procédés de fabrication de ceux-ci et utilisation de ceux-ci en thérapie médicale
EP2081556A1 (fr) 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Compositions d'imatinib stables
EP2062885A1 (fr) * 2007-11-21 2009-05-27 Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. Sels d'addition d'acide d'imatinib et formules les comportant
NZ779754A (en) 2009-01-16 2023-04-28 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl] oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
US20100189790A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100330130A1 (en) * 2009-05-22 2010-12-30 Actavis Group Ptc Ehf Substantially pure imatinib or a pharmaceutically acceptable salt thereof
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
US8933037B2 (en) 2009-09-28 2015-01-13 Medizinische Universitat Wien Methods involving PDGFRBETA inhibitors
PL389357A1 (pl) 2009-10-22 2011-04-26 Tomasz Koźluk Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
KR101138840B1 (ko) * 2009-12-28 2012-05-10 주식회사 셀트리온화학연구소 이마티닙 다이클로로아세트산염 및 이를 포함하는 항암제 조성물
KR20130055576A (ko) 2010-03-15 2013-05-28 낫코 파마 리미티드 고순도의 결정질 이마티닙 염기를 제조하는 방법
EA024088B1 (ru) 2010-06-18 2016-08-31 КРКА, д.д., НОВО МЕСТО α-ФОРМА МЕЗИЛАТА ИМАТИНИБА, СПОСОБЫ ЕЕ ПОЛУЧЕНИЯ И СОДЕРЖАЩАЯ ЕЁ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
WO2012090221A1 (fr) 2010-12-29 2012-07-05 Cadila Healthcare Limited Nouveaux sels d'imatinib
EP2833866B2 (fr) 2012-04-04 2024-11-27 Intervet International B.V. Produits pharmaceutiques mous à mâcher
WO2014016848A2 (fr) 2012-07-24 2014-01-30 Laurus Labs Private Limited Formes solides d'inhibiteurs de tyrosine kinase, procédé pour leur préparation et leur composition pharmaceutique
EP3782604A1 (fr) 2013-07-31 2021-02-24 Windward Pharma, Inc. Composés inhibiteurs de tyrosine kinase en aérosol et leurs utilisations
SI3407874T1 (sl) 2016-01-25 2024-10-30 Krka, D.D., Novo Mesto Hitro disperzibilni farmacevtski sestavek, ki obsega zaviralca tirozin-kinaze
EP3761983A1 (fr) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Stratégie de dosage d'aripiprazole

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
JP3691861B2 (ja) * 1994-09-14 2005-09-07 株式会社東芝 光ディスク用光パルス幅制御装置
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6448293B1 (en) * 2000-03-31 2002-09-10 Pfizer Inc. Diphenyl ether compounds useful in therapy
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US6479692B1 (en) * 2001-05-02 2002-11-12 Nobex Corporation Methods of synthesizing acylanilides including bicalutamide and derivatives thereof
GB0202873D0 (en) * 2002-02-07 2002-03-27 Novartis Ag Organic compounds
US20050124624A1 (en) * 2002-03-15 2005-06-09 Gilbert Richard E. 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-yl-amino)phenyl]-benzamide for threating ang ii-mediated diseases
GB2398565A (en) * 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
JP5844508B2 (ja) * 2005-11-25 2016-01-20 ノバルティス アーゲー メシル酸イマチニブのｆ結晶形

Also Published As

Publication number Publication date
KR20120127525A (ko) 2012-11-21
US20080249104A1 (en) 2008-10-09
JP4937760B2 (ja) 2012-05-23
RU2375355C2 (ru) 2009-12-10
ECSP066752A (es) 2006-11-16
KR20060135735A (ko) 2006-12-29
AU2005211514A1 (en) 2005-08-18
IL177005A (en) 2014-05-28
RU2006131548A (ru) 2008-03-10
PE20051096A1 (es) 2006-01-23
MY144177A (en) 2011-08-15
CN100558723C (zh) 2009-11-11
ZA200605972B (en) 2007-11-28
TW200529854A (en) 2005-09-16
PH12013500157A1 (en) 2014-09-08
CA2553887C (fr) 2013-04-16
IL177005A0 (en) 2006-12-10
AR047530A1 (es) 2006-01-25
US20140051853A1 (en) 2014-02-20
NZ548714A (en) 2009-08-28
TNSN06243A1 (en) 2007-12-03
EP1713792B1 (fr) 2014-04-30
JP2007520518A (ja) 2007-07-26
CN1914191A (zh) 2007-02-14
EP1713792A2 (fr) 2006-10-25
CA2553887A1 (fr) 2005-08-18
NO20063942L (no) 2006-11-02
BRPI0507464A (pt) 2007-07-10
TWI347186B (en) 2011-08-21
US20120142697A1 (en) 2012-06-07
US8513256B2 (en) 2013-08-20
WO2005075454A3 (fr) 2006-07-27
AU2005211514B2 (en) 2009-09-10
WO2005075454A2 (fr) 2005-08-18

Similar Documents

Publication Publication Date Title
MA28428B1 (fr) FORMES SALINES DE 4-(4-METHYLPIPERAZIN-1-YLMETHYL)-n-[4-METHYL-3-(4-PYRIDIN-3-YL)PYRIMIDIN-2-YLAMINO) PHENYL]-BENZAMIDE
RU2009149216A (ru) Бициклические амиды как ингибиторы киназы
ATE321556T1 (de) Behandlung gastrointestinaler stroma-tumoren
ATE536353T1 (de) 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
AR053984A1 (es) Combinacion de un inhibidor de proteina cinasa src y un inhibidor bcr - abl para el tratamiento de enfermedades proliferativas
WO2009065910A3 (fr) Nouveaux sels d'addition acides d'imatinib et formulations les contenant
SI1471916T1 (sl) Zdravljenje revmatoidnega artritisa z imatinibom
HRP20100265T1 (hr) Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti
IL171927A0 (en) Use of tyrosine kinase inhibitor to treat diabetes
NO20072501L (no) Anvendelse av 4-(4-metyopiperazin-1-ylmetyl)-N-[4-metyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid for a inhibere tyrosin kinasereseptor C-FMS
WO2004026930A3 (fr) Composes organiques
ATE326970T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
WO2004103374A3 (fr) Traitement des cancers de la tete ou du cou
TH74677A (th) รูปเกลือของ 4-[(4-เมทธิลปิปเปอราซิน-1-อิลเมทธิล)-n-[4-เมทธิล-3-(4-ไพริดิน-3-อิล)ไพริมิดิน-2-อิลอะมิโน)เฟนนิล]-เบนซามีด
TNSN05304A1 (en) Use of tyrosine kinase inhibitor to treat diabetes
HK1097535A (en) Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide